Chonnam National University Hwasun Hospital
Hwasun, South Korea
56 recruiting
Showing 1–20 of 78 trials
Recruiting
Phase 3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Extensive-stage Small Cell Lung Cancer (ES-SCLC)Small Cell Lung Cancer ( SCLC )
Boehringer Ingelheim670 enrolled242 locationsNCT07472517
Recruiting
Phase 3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals915 enrolled20 locationsNCT07222761
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled320 locationsNCT06561386
Recruiting
Phase 3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
HR+/HER2- Breast Cancer
BeOne Medicines1,056 enrolled74 locationsNCT07492641
Recruiting
Phase 3
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Multiple Myeloma
Hoffmann-La Roche380 enrolled15 locationsNCT07555938
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled84 locationsNCT04929223
Recruiting
Phase 3
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Chronic Lymphocytic LeukemiaCLL
BeOne Medicines250 enrolled124 locationsNCT06846671
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Hoffmann-La Roche400 enrolledNCT07541170
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled366 locationsNCT06890598
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled419 locationsNCT06119581
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Hemophilia A
Hoffmann-La Roche126 enrolled2 locationsNCT07416526
Recruiting
Phase 2Phase 3
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled195 locationsNCT04534205
Recruiting
Phase 2
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled78 locationsNCT07185997
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC641 enrolled193 locationsNCT06319820
Recruiting
Phase 3
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC1,203 enrolled172 locationsNCT07164443
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC700 enrolled88 locationsNCT07518186
Recruiting
Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC157 enrolled71 locationsNCT07266441
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled270 locationsNCT05552222